S P Newman

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Regulation of steroid sulphatase expression and activity in breast cancer
    S P Newman
    Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary s Hospital, W2 1NY, London, UK
    J Steroid Biochem Mol Biol 75:259-64. 2000
  2. pmc BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
    J M Day
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 100:476-86. 2009
  3. pmc In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
    S K Chander
    Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 96:1368-76. 2007
  4. pmc The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
    S P Newman
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 97:1673-82. 2007
  5. pmc 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
    S L C Tagg
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 99:1842-8. 2008
  6. pmc The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
    M F C Parsons
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 99:1433-41. 2008
  7. pmc Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents
    C Stengel
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 102:316-24. 2010
  8. ncbi request reprint Steroid sulphatase inhibitors for breast cancer therapy
    A Purohit
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    J Steroid Biochem Mol Biol 86:423-32. 2003
  9. ncbi request reprint Steroid sulfatase: molecular biology, regulation, and inhibition
    M J Reed
    Endocrinology and Metabolic Medicine, Imperial College, St Mary s Hospital, London W2 1NY, United Kingdom
    Endocr Rev 26:171-202. 2005
  10. ncbi request reprint The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells
    T Utsumi
    Endocrinology and Metabolic Medicine, Imperial College Faculty of Medicine, St Mary s Hospital and Sterix Ltd, London, W2 1NY, UK
    J Steroid Biochem Mol Biol 94:219-27. 2005

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Regulation of steroid sulphatase expression and activity in breast cancer
    S P Newman
    Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary s Hospital, W2 1NY, London, UK
    J Steroid Biochem Mol Biol 75:259-64. 2000
    ..In conjunction with the lack of regulation of STS mRNA it suggest that TNFalpha and IL-6 may increase STS activity via a post-translational modification of the enzyme or by increasing substrate availability...
  2. pmc BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
    J M Day
    Department of Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 100:476-86. 2009
    ..This is despite an increase in BCRP expression in A2780 cells in vitro after chronic dosing with STX140...
  3. pmc In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
    S K Chander
    Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 96:1368-76. 2007
    ..This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further development for cancer therapy...
  4. pmc The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
    S P Newman
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 97:1673-82. 2007
    ..In contrast to the taxanes, STX140 can be dosed orally, with no toxicity being observed even after prolonged daily dosing...
  5. pmc 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
    S L C Tagg
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 99:1842-8. 2008
    ..This is the first study to show the benefit of combining a microtubule disruptor with 2DG in the two most common solid tumours...
  6. pmc The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
    M F C Parsons
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 99:1433-41. 2008
    ..These results show that STX243 is a potent in vivo drug and could be clinically effective at treating a number of oncological conditions...
  7. pmc Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents
    C Stengel
    Oncology Drug Discovery and Women s Health Group, Faculty of Medicine, Imperial College London, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 102:316-24. 2010
    ....
  8. ncbi request reprint Steroid sulphatase inhibitors for breast cancer therapy
    A Purohit
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    J Steroid Biochem Mol Biol 86:423-32. 2003
    ..Second generation inhibitors, such as 2-MeOE2bisMATE, which also inhibit the growth of ER- tumours should be active against a wide range of cancers...
  9. ncbi request reprint Steroid sulfatase: molecular biology, regulation, and inhibition
    M J Reed
    Endocrinology and Metabolic Medicine, Imperial College, St Mary s Hospital, London W2 1NY, United Kingdom
    Endocr Rev 26:171-202. 2005
    ..The development of potent STS inhibitors will allow investigation of the role of this enzyme in physiological and pathological processes...
  10. ncbi request reprint The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells
    T Utsumi
    Endocrinology and Metabolic Medicine, Imperial College Faculty of Medicine, St Mary s Hospital and Sterix Ltd, London, W2 1NY, UK
    J Steroid Biochem Mol Biol 94:219-27. 2005
    ....
  11. ncbi request reprint The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer
    A Purohit
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    Mol Cell Endocrinol 248:199-203. 2006
    ..The identification of potent, selective novel 17beta-HSD1 inhibitors will allow their efficacy to be tested in in vitro and in vivo studies...
  12. pmc Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents
    C R Ireson
    1Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    Br J Cancer 90:932-7. 2004
    ..The resistance to metabolism shown by 2-MeOE2bisMATE and its ability to inhibit tumour growth in vivo suggest that this compound should have considerable potential for development as a novel anticancer drug...
  13. ncbi request reprint The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis
    Y T Ho
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    J Steroid Biochem Mol Biol 86:189-96. 2003
    ....
  14. ncbi request reprint Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates
    Y T Ho
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    Biochem Biophys Res Commun 305:909-14. 2003
    ....
  15. ncbi request reprint Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate
    R N Suzuki
    Endocrinology and Metabolic Medicine and Sterix Ltd, Faculty of Medicine, Imperial College, St Mary s Hospital, London W2 1NY, UK
    J Steroid Biochem Mol Biol 84:269-78. 2003
    ....
  16. ncbi request reprint Inhibition of oestrone sulphatase activity by tibolone and its metabolites
    A Purohit
    Dept of Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary s Hospital, London, W2 1NY, UK
    Horm Metab Res 34:1-6. 2002
    ..Results from this study have confirmed that tibolone and its metabolites can inhibit E1-STS activity. This may explain the absence of breast stimulation as observed in clinical studies...
  17. ncbi request reprint Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer
    S P Newman
    ICRF Molecular Oncology Unit, ICSM Hammersmith Hospital, London, UK
    Oncogene 19:490-7. 2000
    ....
  18. doi request reprint Religious coping strategies in patients diagnosed with breast cancer in the UK
    I C V Thuné-Boyle
    Unit of Behavioural Medicine, Division of Research Strategy, UCL, London, UK
    Psychooncology 20:771-82. 2011
    ..The aim of this study was to examine the prevalence of various religious coping strategies in a UK cancer sample...